{"id":"an2728-ointment-2","safety":{"commonSideEffects":[{"rate":"unknown","effect":"Skin atrophy"},{"rate":"unknown","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the production of pro-inflammatory cytokines and enzymes, thereby reducing the symptoms of skin conditions such as eczema and psoriasis. The exact mechanism of action is not fully understood, but it is thought to involve the suppression of the immune system's response to allergens and irritants.","oneSentence":"AN2728 ointment, 2% is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:31.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eczema"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT07367932","phase":"PHASE4","title":"Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Dermatitis, Atopic, Eczema","enrollment":30},{"nctId":"NCT07162896","phase":"PHASE3","title":"Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2026-06","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD)","enrollment":66},{"nctId":"NCT07088276","phase":"NA","title":"Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-08","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT04194814","phase":"PHASE2","title":"Skin bioMARkers for Atopic Eczema Therapy Evaluation","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2020-11-20","conditions":"Atopic Eczema/Dermatitis (Non-Specific)","enrollment":37},{"nctId":"NCT03250663","phase":"PHASE1","title":"Eucrisa for Atopic Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-01","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":28},{"nctId":"NCT05200403","phase":"PHASE4","title":"Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-07-26","conditions":"Atopic Dermatitis","enrollment":72},{"nctId":"NCT04299503","phase":"PHASE2","title":"Topical Crisaborole in Patients with Alopecia Areata","status":"WITHDRAWN","sponsor":"Tufts Medical Center","startDate":"2020-03-06","conditions":"Alopecia Areata","enrollment":""},{"nctId":"NCT05298033","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-09-07","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT04800185","phase":"EARLY_PHASE1","title":"Characterizing Skin Microbiome Change in Atopic Dermatitis","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2021-03-23","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema","enrollment":20},{"nctId":"NCT04040192","phase":"PHASE3","title":"A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-12","conditions":"Atopic Dermatitis","enrollment":620},{"nctId":"NCT04023084","phase":"PHASE4","title":"Response of Children With Atopic Dermatitis (Eczema) to Eucrisa","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2019-10-03","conditions":"Atopic Dermatitis, Eczema","enrollment":30},{"nctId":"NCT04360187","phase":"PHASE3","title":"Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-27","conditions":"Atopic Dermatitis","enrollment":391},{"nctId":"NCT04091087","phase":"PHASE2","title":"Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-26","conditions":"Stasis Dermatitis","enrollment":66},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT03567980","phase":"PHASE4","title":"A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-01","conditions":"Seborrheic Dermatitis","enrollment":30},{"nctId":"NCT03868098","phase":"PHASE4","title":"Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2019-05-21","conditions":"Dermatitis, Atopic","enrollment":31},{"nctId":"NCT04498403","phase":"PHASE3","title":"A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-09-14","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT04008784","phase":"","title":"Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period","status":"COMPLETED","sponsor":"Clinical Research Center of the Carolinas","startDate":"2019-09-16","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT03351114","phase":"PHASE2","title":"Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-09-01","conditions":"Morphea","enrollment":8},{"nctId":"NCT04214197","phase":"PHASE4","title":"Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT03954158","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-15","conditions":"Atopic Dermatitis","enrollment":81},{"nctId":"NCT03356977","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-16","conditions":"Atopic Dermatitis","enrollment":137},{"nctId":"NCT03233529","phase":"PHASE2","title":"Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-31","conditions":"Dermatitis, Atopic","enrollment":40},{"nctId":"NCT03760042","phase":"PHASE1","title":"Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-14","conditions":"Healthy","enrollment":32},{"nctId":"NCT01258088","phase":"PHASE1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11-30","conditions":"Plaque-type Psoriasis","enrollment":16},{"nctId":"NCT03260595","phase":"PHASE1","title":"A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-13","conditions":"Healthy, Atopic Dermatitis","enrollment":32},{"nctId":"NCT00762658","phase":"PHASE1","title":"A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11-30","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT01301508","phase":"PHASE2","title":"Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Dermatitis, Atopic","enrollment":46},{"nctId":"NCT01652885","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Dermatitis, Atopic","enrollment":23},{"nctId":"NCT01300052","phase":"PHASE2","title":"AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01-26","conditions":"Psoriasis","enrollment":68},{"nctId":"NCT01029405","phase":"PHASE2","title":"Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Psoriasis","enrollment":145},{"nctId":"NCT01602341","phase":"PHASE2","title":"Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Dermatitis, Atopic","enrollment":86},{"nctId":"NCT00755196","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02118766","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":763},{"nctId":"NCT02118792","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":764},{"nctId":"NCT00759161","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Psoriasis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AN2728 ointment, 2%","genericName":"AN2728 ointment, 2%","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2728 ointment, 2% is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response. Used for Eczema, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}